The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (tumorgraft) models. A secondary aim of the study was to evaluate whether JQ1 decreases expression of the oncogene c-Myc in PDAC tumors, as has been reported for other tumor types. We used five PDAC tumorgraft models that retain specific characteristics of tumors of origin to evaluate the antitumor efficacy of JQ1. Tumor-bearing mice were treated with JQ1 (50 mg/kg daily for 21 or 28 days). Expression analyses were performed with tumors harvested from host mice after treatment with JQ1 or vehicle control. An nCounter PanCancer Pathways Panel (NanoString Technologies) of 230 cancer-related genes was used to identify gene products affected by JQ1. Quantitative RT-PCR, immunohistochemistry and immunoblots were carried out to confirm that changes in RNA expression reflected changes in protein expression. JQ1 inhibited the growth of all five tumorgraft models (P o 0.05), each of which harbors a KRAS mutation; but induced no consistent change in expression of c-Myc protein. Expression profiling identified CDC25B, a regulator of cell cycle progression, as one of the three RNA species (TIMP3, LMO2 and CDC25B) downregulated by JQ1 (P o0.05). Inhibition of tumor progression was more closely related to decreased expression of nuclear CDC25B than to changes in c-Myc expression. JQ1 and other agents that inhibit the function of proteins with bromodomains merit further investigation for treating PDAC tumors. Work is ongoing in our laboratory to identify effective drug combinations that include JQ1.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer (PC), is a highly aggressive malignancy of the exocrine pancreas and accounts for~40 000 patient deaths annually. 1 Among adult solid tumors PC ranks as the fourth leading cause of cancer-related deaths in the United States, with an overall 5-year survival of 6%.
1,2 PDAC is distinguished by late clinical presentation, making~80% of patients ineligible for surgical resection. Patients that do undergo resection have a marginally better 5-year survival of 15-20%. 3 Chemotherapy, often combined with radiotherapy, is the primary treatment for most patients presenting with advanced or metastatic disease. The nucleoside analog gemcitabine has been the standard of care for PDAC patients for over a decade, but effective treatment remains challenging. 4, 5 Intuitively, profiles of molecular and genetic abnormalities characteristic of a given tumor type would suggest effective drugtargeting strategies. Genetic abnormalities that occur frequently in PDAC tumors include mutations that constitutively activate the KRAS oncogene, that silence the tumor suppressor TP53, or that promote cell cycle progression regulated by CDKN2A. [6] [7] [8] A detailed genomic analysis of 24 primary PDAC tumors showed a set of 12 pathways that were altered in 67-100% of tumors analyzed. 9 Those data suggested that the epidermal growth factor receptor pathway likely contributes to progression of PDAC tumors. 9 A second commonly dysregulated pathway in PDAC and other solid tumors involves c-Myc, a basic helix-loop-helix leucine zipper transcription factor thought to influence expression of~15% of the genome responsible for cell growth, proliferation and apoptosis. c-Myc is amplified in 430% and overexpressed in 440% of PDAC tumors. 10 Consistent with these observations, increased expression of c-Myc in a genetically engineered mouse model of PC induces tumor formation. 11 Although the importance of c-Myc in cancer progression is well documented, until recently it has been difficult to target this oncogene. Delmore et al. 12 determined that the bromodomain and extraterminal (BET) family of proteins regulate c-Myc expression and function. BET proteins such as bromodomaincontaining 4 (BRD4) recruit proteins comprising macromolecular transcription complexes to specific chromatin sites. BET proteins (BRD2, BRD3, BRD4 and BRDT) possess an extraterminal domain and tandem bromodomains that recognize acetylated lysine 
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Nuclear Cytoplasmic residues on histones. JQ1 binds to the domain of BET proteins that interacts with histones, thereby competitively inhibiting binding of BET proteins to chromatin and decreasing expression of RNA species dependent on this mechanism of transcription. 13 One such RNA species is that encoding c-Myc, as BRD4 is required to recruit p-TEFb to initiate transcription of c-Myc. 12 Inhibition of c-Myc expression is thought to be an essential mechanism by which BET inhibitors suppress tumor progression in hematological malignancies. [14] [15] [16] JQ1 has shown efficacy in preclinical models of a variety of tumor types including multiple myeloma, medulloblastoma, NUT midline carcinoma, neuroblastoma and glioblastoma. [17] [18] [19] [20] [21] In the present study, we used five PDAC tumorgraft models, each of which expresses relatively high levels of c-Myc protein, to evaluate the impact of the BET inhibitor JQ1 on tumor growth. We also compared expression of 230 cancer-related genes to identify gene products affected by JQ1. JQ1 suppressed tumor growth in all tumorgraft models. However, we observed no consistent association between inhibition of tumor growth in vivo and decreased c-Myc expression. JQ1 did inhibit expression of CDC25B, a regulator of cell cycle progression.
RESULTS

Clinical characteristics of tumors of origin
The models used in this study (UAB-PA3, -PA4, -PA10, -PA30 and -PA36) were derived from tumors of patients who underwent surgery as a standard of care at the University of Alabama at Birmingham Hospital. 22 Models were derived from tumors of patients with stage II PDAC, with three of the five patients having lymph node involvement at the time of surgical resection ( Figure 1a ). All primary tumors had mutations in codon 12 of the KRAS gene. These models were chosen for their readily detectable expression of c-Myc by immunohistochemistry (IHC; Figure 1b ).
PDAC primary tumors express higher levels of c-Myc than normal pancreas IHC analysis of formalin-fixed paraffin-embedded tissues demonstrated minimal-to-high (1+ to 3+) nuclear expression and intermediate-to-high (2+ to 3+) cytoplasmic expression of c-Myc protein in all primary tumors of origin ( Figure 1b ). Normal pancreatic tissue had foci of predominantly cytoplasmic c-Myc in both ductal and acinar tissue. Overall, c-Myc expression was relatively low in normal pancreas (expression index 80) compared to primary tumors (expression indices 180-270). IHC analyses demonstrated similar levels of c-Myc in tumorgraft models and their tumors of origin with the exception of UAB-PA4 tumors, which expressed less nuclear c-Myc protein than the tumor from which it was derived ( Figure 1c ). UAB-PA4 also had a lower ratio of nuclear:cytoplasmic c-Myc protein, but the impact of this change in the ratio of cell phenotype is unclear. Immunoblot analyses confirmed a readily detectable level of c-Myc protein in all models (Figure 1d ). Because the cytotoxicity of JQ1 has been reported to depend on downregulation of c-Myc, 19, 23 we next evaluated the effect of JQ1 on tumor cell morphology, tumor growth in vivo and on c-Myc expression in these tumors. JQ1 suppressed tumor growth in vivo in preclinical models of PDAC To evaluate the efficacy of JQ1, we administered a well-tolerated regimen of JQ1 (50 mg/kg daily × 28 or 21 days) to mice bearing PDAC tumorgrafts. JQ1 inhibited tumor growth by 40-62% compared to vehicle control (VC) in all five independently derived models ( Figure 2a ). Model UAB-PA36 was the least responsive to JQ1 treatment with a difference in tumor volume being observed only on the final day of treatment. Time to detection of a JQ1-induced decrease in tumor volume ranged from day 14 (UAB-PA4) to day 28 (UAB-PA36).
We corroborated the effect of JQ1 on tumor volume by immunostaining for the proliferation marker Ki67. Proliferation index was defined as the percentage of nuclei with detectable Ki67 expression, using photomicrographs imaged using Photoshop CS4 (Adobe Systems Incorporated, San Jose, CA, USA) (Figures 2b and c) . Ki67 staining of UAB-PA3, -PA4, -PA10 and -PA30 tumors was decreased in JQ1-compared to VC-treated mice indicating that fewer tumor cells were traversing the cell cycle in the JQ1-treated animals. Consistent with the minimal effect of JQ1 on UAB-PA36 tumors, no difference was seen in the proliferation index of tumors from treated versus control mice bearing this tumor. The data demonstrate that JQ1 inhibited the growth of five PDAC tumor models and decreased the proliferation index in four of the five models of independent origin. The fifth model, UAB-PA36, showed no decrease in proliferation index and was least sensitive to the cytotoxicity of JQ1 in vivo.
JQ1-induced apoptosis in a subset of models Tumors were harvested 24 or 48 h after termination of treatment, and their histology compared using formalin-fixed paraffinembedded sections stained with hematoxylin and eosin ( Figure 3a) . JQ1 increased the number of apoptotic (white arrows) and necrotic (yellow arrows) tumor cells in the UAB-PA10 and -PA30 models, each of which was responsive to JQ1. JQ1 also induced a slight reduction in peritumoral stroma of tumorgraft models UAB-PA3, -PA4 and -PA10 (white circles; Figure 3a) , and an increase in stromal hyalinization in UAB-PA3, -PA10 and -PA30 (green circles). Consistent with minimal decrease in tumor growth, UAB-PA36 tumors from JQ1-treated mice had decreases in nuclear atypia and increases in nuclear:cytoplasmic ratio, but no apparent increase in apoptotic or necrotic tumor cells. Of interest, JQ1 appeared to induce tumor cell differentiation in UAB-PA4 tumors (Figure 3a ; × 40 image, right panel), with tumor cells having more well-preserved nuclear polarity, less nuclear polymorphism and stratification, and a lower nuclear:cytoplasmic ratio than tumor cells from VC-treated mice. This observation is consistent with a previous report showing that JQ1-induced squamous cell differentiation of 797NUT midline carcinoma cells. 19 However, UAB-PA4 was the only model that showed differentiation after JQ1 treatment. As JQ1 has been reported to exert its antitumor effect by suppressing c-Myc expression in hematological and solid tumors, 15, 17, 19, [24] [25] [26] [27] [28] we next examined whether suppression of tumor growth was coincident with decreased expression of c-Myc in PDAC tumorgrafts.
JQ1 inhibited expression of c-Myc RNA, but had no consistent effect on c-Myc protein We evaluated c-Myc expression in tumorgrafts exposed to JQ1 compared to VC by expression array (NanoString Technologies, Seattle, WA, USA), qRT-PCR and immunoblot. First, array results failed to demonstrate a difference in c-Myc RNA levels in tumors from JQ1-compared to VC-treated mice (data not shown). Second, a qRT-PCR method 29 and human-specific c-Myc primer set showed that JQ1-treated tumors expressed~17-30% less c-Myc RNA than VC-treated tumors (Figure 3b ), values that were regarded as minimal but that were statistically significant in four of the five models. The discrepancy between expression array data and qRT-PCR data was attributed to the marginal decrease, if any, in c-Myc RNA induced by JQ1. Third, to determine whether the putative decrease in c-Myc RNA reflected decreased protein expression, we assessed c-Myc by immunoblot and IHC. Immunoblots detected no effect of exposure to JQ1 on c-Myc protein and increased expression of this oncogene in tumorgrafts compared to normal pancreas (Figure 3c ). IHC detected a decrease (~1.8-fold) in c-Myc protein only in one model (UAB-PA10; Figures 3d and e) . The other four models showed o 10% nuclear immunoreactivity and expression indices of 100-200 with moderate staining intensity of tumors from both JQ1-and VC-treated mice. We concluded that JQ1 had little effect on levels of c-Myc protein in these PDAC models. Further, although JQ1 is thought to inhibit cell growth by inhibiting BRD4 function rather than expression, we verified that BRD4 protein levels were also unaffected by exposure to JQ1. IHC data detected no consistent changes in level of expression or subcellular localization of c-Myc or BRD4 protein (Figures 3d and e) .
The minimal decrease in RNA encoding c-Myc suggested by qRT-PCR data was not seen in the NanoString assay or by immunoblots, as mentioned above. However, to rule out an effect of JQ1 on c-Myc function, we evaluated the effect of JQ1 on transcriptional targets of c-Myc, and found that only 1 of 19 gene products that have been reported to be transcriptional targets of c-Myc was decreased in all five models, following exposure to JQ1 (Figure 4a ). This observation suggests that c-Myc function was unaffected and is unlikely to be critical to the cytotoxic mechanism of JQ1 in PDAC tumors. Of note, the list of putative transcriptional targets of c-Myc in Figure 4a was compiled from multiple references that demonstrate the likelihood of regulation by c-Myc in various types of cells and tissues. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] The genes listed do not necessarily represent transcriptional targets of c-Myc in PDAC tumors. The single exception to this observation may be CDC25B, and is discussed below. The regulatory region of CDC25B has been reported to have a single Myc/Max binding site, 47 and is regarded as a potential c-Myc transcriptional target.
The data suggest that inhibition of growth of PDAC tumors may be independent of downregulation of c-Myc, as has been suggested by findings using ex vivo systems, higher doses of JQ1 (100-500 nM, 2.5 μM), and lung adenocarcinoma and glioblastoma cells. 21, 49 To identify alternative gene products whose upregulation or downregulation might be affected by BRD4 inhibition and that might contribute to the mechanism of cytotoxicity of JQ1, we ranked the NanoString data to identify the 30 genes whose expression was decreased to the greatest extent, following exposure to JQ1. We also investigated the effect of exposure of JQ1 on CDC25B expression.
JQ1 altered the expression of nine gene products in all five models The 30 gene products most affected by JQ1, as evaluated by NanoString, are listed in Supplementary Table S1 . The values in the Table represent the average change among the five models, but do not necessarily reflect similar changes in each of the five models. A Partek Genomic Suite program (Partek Incorporated, St Louis, MO, USA) identified six RNA species commonly upregulated and three RNA species commonly downregulated in the five models (Figures 4b and c) . Figure 4b shows a heatmap of these nine genes (blue = downregulation; red = upregulation; see Materials and Methods section for details). Exposure to JQ1 increased expression of PTEN, CASP2, MSH6, BRAF, NOTCH11 and ERCC4 by 1.1-to 1.8-fold (P = 0.026, 0.028, 0.033, 0.035, 0.036 and 0.048, respectively), and decreased expression of LMO2, TIMP3 and CDC25B by 1.3-to 1.4-fold (P = 0.026, 0.032 and 0.048, respectively; Figure 4c ). The change in expression of each of these RNAs was less than twofold and none appears in the list of most affected genes. The potential involvement of CDC25B was investigated further based on the following considerations. Heat map results indicated a uniform downregulation of CDC25B in all five PDAC tumorgraft models. CDC25B has been reported to be an oncogene 50 and to be overexpressed in PDAC tumors, 51 and targeted CDC25B inhibitors inhibit the growth of PC cell lines. CDC25B (cell division cycle 25B) belongs to a family of cell cycle phosphatases (CDC25A, CDC25B and CDC25C) that regulate cell cycle progression by dephosphorylation of cyclin-dependent kinases, thereby activating cyclin-dependent kinase/cylin complexes and stimulating cell proliferation. CDC25B accumulates in the nucleus during the G2 phase of the cell cycle to initiate entry into mitosis. 52, 53 Expression of CDC25B, a member of the CDC25 phosphatase family qRT-PCR analyses confirmed a JQ1-dependent reduction in the expression of CDC25B RNA in three models (Figure 5a ; Po 0.05); but as was seen with c-Myc expression the degree of decrease was less than twofold. Immunoblot data demonstrated that JQ1 decreased CDC25B protein expression by 33% (UAB-PA3) to 99% (UAB-PA4) in the four tumorgraft models most sensitive to JQ1 (Figure 5b ). Expression indices demonstrated that exposure to JQ1 decreased expression of nuclear CDC25B from 33% (UAB-PA10) to 83% (UAB-PA4; Figure 5c ). No decrease in CDC25B protein was observed in the model least sensitive to JQ1 (UAB-PA36).
Further, we demonstrated a dose-response relationship between concentration of JQ1, CDC25B protein expression and inhibition of cell growth using an in vitro model. We exposed BxPC3 PC cells to JQ1 to determine the IC 50 and to evaluate the level of expression of CDC25B protein over a range of JQ1 concentrations (10 . The data demonstrate a simultaneous inhibition of cell growth and decrease in CDC25B expression.
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UAB In summary, data from in vivo models demonstrate that exposure to JQ1 inhibited CDC25B expression in tumor models most sensitive to this agent. In vitro data demonstrated dose-dependent decreases in BxPC3 cell viability and CDC25B protein by JQ1. The data also suggest that decreased expression of c-Myc is unlikely to be a primary mechanism by which JQ1 inhibits PDAC cell growth, as we observed no consistent change in c-Myc RNA or protein expression, or function as assessed by the level of expression of transcriptional targets of this transcription factor. In vivo data demonstrating JQ1-mediated inhibition of tumor progression indicate that bromodomain inhibitors merit further investigation for treatment of PDAC tumors as single agents and in combination.
DISCUSSION
The main goal of this study was to evaluate the efficacy of the bromodomain inhibitor JQ1 in tumorgraft models of PDAC. A secondary goal was to evaluate the likelihood that the mechanism of cytotoxicity of JQ1 in this tumor type depends on downregulating c-Myc expression, as has been reported. 19 The main findings of the study were that a well-tolerated (nontoxic) regimen of JQ1 reduced relative tumor volume by 40-62% in five independently derived models and that JQ1 did not consistently impact expression of c-Myc protein or its transcriptional targets. The data did show a dose-dependent decrease in CDC25B expression in vitro and inhibition of tumorgraft growth by JQ1 in vivo. Our study is unique in its evaluation of the efficacy of JQ1 in PDAC tumors using independently derived tumorgraft models that harbor KRAS mutations and in its demonstration that exposure to JQ1 decreases CDC25B expression in PDAC tumor cells sensitive to this agent. No published studies have evaluated the antitumor effects of JQ1 in tumorgraft models of PC. The literature does report the efficacy of JQ1 for a variety of malignant cell types including lung cancer, glioblastoma, medulloblastoma, neuroblastoma and hematological malignancies. 18, 20, 21, 24, 26, 49 Model systems used range from cell lines and ex vivo systems to transgenic mice. 21, 28, 49 Relevant to this study, Sahai et al. 54 demonstrated that JQ1 and BRD4 knockdown suppressed proliferation of pancreatic tumor cells in an in vitro three-dimensional collagen model. Mechanistically, JQ1 competitively inhibits the BET proteins such as BRD4 from binding to acetylated lysine residues of histones, thereby preventing the association of transcriptional complexes with chromatin. 12, 19 Multiple other studies suggest that a critical mechanism by which JQ1 inhibits tumor cell growth is its effect on c-Myc expression through BET protein inhibition. 13, 19 Data for this hypothesis have been generated primarily with hematologic Lockwood et al. 55 reported that a subset of lung adenocarcinoma cell lines was sensitive to JQ1 and that this sensitivity did not correlate with c-Myc downregulation. The authors identified the transcription factor FOS-like antigen 1, which was downregulated by JQ1 treatment and BRD4 knockdown. 55 In addition, Fowler et al. 28 demonstrated that JQ1 did not inhibit c-Myc expression in all tumor types. The authors proposed c-Myc expression might be regulated by multiple transcriptional and epigenetic mechanisms. 28 Our data suggest the involvement of CDC25B in pancreatic tumor cells. Although JQ1 is considered to be a targeted agent for the BET proteins, BRD4 in particular is a component of a transcription process that affects multiple RNA species, including c-Myc. c-Myc, in turn, is a transcription factor that regulates expression of a myriad of gene products. Taken together, the data suggest that the efficacy of JQ1 may result from effects on multiple cellular proteins and processes downstream of BRD4. Of interest, particularly in light of the numerous gene products dependent on BRD4-associated transcription, is the observation that JQ1 is well tolerated at doses up to 100 mg/kg in murine models. 13, 56 With respect to our observation that CDC25B is one of the proteins affected by JQ1, we note that Guo et al. 51 showed that two targeted CDC25B inhibitors (NSC663284 and NSC668394) inhibited the growth of PC cells in vitro by inducing a G2/M cell cycle arrest. This work demonstrated that pharmacologic inhibition of CDC25B was sufficient to inhibit cell cycle progression of PDAC tumor cells. In addition, Yu et al. 57 reported that knockdown of CDC25B in renal cell carcinoma cells was associated with reduced migratory and invasive potential, characteristics of a less malignant phenotype. Our observations with in vivo models are consistent with published in vitro and in vivo findings, and emphasize the potential utility of treating PDAC tumors with BET or CDC25B inhibitors. The data suggest that decreased CDC25B expression, either as a potential downstream target of c-Myc 47 or by an as yet unknown mechanism, likely contributes to PDAC tumor growth inhibition.
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Regarding the effect of JQ1 on PDAC tumor growth, our data demonstrate the inhibitory effect of this BRD4 inhibitor on subcutaneous tumors derived from primary human PDAC tumors. This preclinical model is restricted to the use of early-passage tumors, and each of the five models used retain specific genetic and molecular characteristics of the primary tumors from which they were derived. We propose that this model system has relevance in evaluating the efficacy of novel agents for the treatment of PDAC. An alternative preclinical model of orthotopic PDAC will be used in the future to compare the effect of JQ1 on the metastatic potential and pattern of tumor progression of PDAC tumors, as orthotopic models described by Hoffman and colleagues [58] [59] [60] [61] [62] [63] [64] retain metastatic properties of PDAC tumors that are not accurately assessed using subcutaneous models.
In conclusion, JQ1 suppressed the growth of five independently derived PDAC tumorgraft models and decreased expression of CDC25B. In vitro data indicated a dose-response relationship between concentration of JQ1 and decrease in CDC25B expression. We propose that JQ1 merits further evaluation for efficacy in treating PDAC tumors, alone and in combination with other agents.
MATERIALS AND METHODS
Ethics statement
This study included human subjects and vertebrate animals. All protocols and procedures were approved by the University of Alabama at Birmingham Institutional Review Board or the University of Alabama at Birmingham Institutional Animal Care and Use Committee. 
Patient-derived xenograft (tumorgraft) models
Female severe combined immunodeficiency (SCID) CB 17 − / − mice, 4-6 weeks old (Taconic Farms, Newton, MA, USA) were housed under barrier conditions with a 12-h light/dark cycle and ad libitum access to food and water. Methods for development, transplantation and characterization of tumorgrafts generated directly from surgical specimens were reported previously. 22 Treatment of tumor-bearing mice
We prepared JQ1 according to published procedures. 19 When transplanted tumors reached~100-200 mm 3 in size, we randomized mice (8 or 10 tumors per group), and administered 50 mg/kg JQ1 or VC intraperitoneally daily for 21 (UAB-PA4) or 28 (UAB-PA3, -PA10, -PA30 and -PA36) days. We measured tumor size with Vernier calipers (Fowler/Sylvac, Newton, MA, USA) twice weekly, and calculated tumor volume assuming a perfect sphere and the equation v = (π/6) × d NanoString nCounter RNA expression analysis Total RNA was isolated from frozen specimens by Trizol (Ambion Life Technologies, Carlsbad, CA, USA) Chloroform (Sigma, St Louis, MO, USA) extraction. RNA samples (400 ng) were analyzed in the UAB Nanostring Laboratory (http://www.uab.edu/medicine/radonc/en/nanostring) using an nCounter Analysis System (NanoString Technologies). 65 Briefly, two human sequence-specific capture probes comprised of a human sequence-specific oligonucleotide plus a short common sequence linked to biotin were constructed. RNA + capture probe + fluorescence-labeled reporter probes complementary to capture probes were placed in a hybridization chamber under conditions allowing formation of triplex (mRNA + capture probe + reporter probe) aggregates. Excess probe and partial complexes were removed by affinity purification. Probe/mRNA complexes were loaded into streptavidin-coated cartridges, to immobilize triplexes within the cartridge. Current applied to the cartridge aligned and extended the complexes to facilitate imaging. An nCounter Digital analyzer (NanoString Technologies) acquired digital images of the fluorescence-labeled target mRNA affixed to the cartridge using a charged coupled device camera and microscope objective. Digital images of 230 cancer-related genes (Cancer Reference Panel) were analyzed to detect unique 'barcodes' corresponding to the gene of interest. Expression level was quantitated by comparison with six reference genes.
Data analysis was conducted with nSolver v1.1 software (NanoString Technologies) after normalizing for variations in binding efficiency, hybridization and purification using spiked-in positive controls and normalizing background values using negative control probes. Data are reported as fold difference in expression between JQ1-and VC-treated tumors.
Histological analysis: hematoxylin and eosin staining Fresh tumor tissue was placed for 24 h in 10% neutral buffered formalin (Fisher Scientific, Suwanee, GA, USA) immediately after harvest and then embedded in paraffin. Thin sections (5 μm) were prepared by the Comparative Pathology Laboratory at UAB (Birmingham, AL, USA). Hematoxylin and eosin staining was performed as previously described. 22 Immunohistochemistry Slides containing thin sections of tumor specimens were baked at 60°C, deparaffinized in xylene, and rehydrated using a decreasing ethanol gradient. After antigen retrieval, endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol. Non-specific protein binding was minimized by incubation in 10% horse serum (Vector Laboratories, Burlington, CA, USA), and primary antibody binding was accomplished by overnight incubation. Antibody binding was detected using ImmPRESS secondary reagent (Vector Laboratories) and DAB high contrast chromogen (Scytek Laboratories, Logan, UT, USA). Tissues were counterstained with Harris's hematoxylin (Fisher Scientific). Photomicrographs were taken using an Olympus BH-2 microscope with DP70 camera and DPS-BSW v3.1 software (Center Valley, PA, USA). Proliferation indices: 66 10 random high-power fields (×400) were taken, and positive nuclei counted and divided by the total number of nuclei in two independent experiments. Expression index = % of positive cells × staining intensity (1+ 2+ or 3+). 67 Real-time RT-PCR, qRT-PCR Total RNA (2 μg) was used as the template for cDNA synthesis, using the SuperScript III synthesis kit (Invitrogen, Carlsbad, CA, USA). 2x SsoFast EvaGreen cocktail (Bio-Rad Laboratories, Hercules, CA, USA) was diluted with nuclease-free water and combined with cDNA and appropriate primers. c-Myc forward: 5′-CGACTCTGAGGAGGAACAAG-3′, c-Myc reverse: 5′-GTGATCCAGACTCTGACCTT-3′; GAPDH forward: 5′-AACATCATCCCTGCTT CCAC-3′, GAPDH reverse: 5′-GACCACCTGGTCCTCAGTGT-3′; and CDC25B forward: 5′-GTGATCCCAGGTGACGACAT-3′, CDC25B reverse: 5′-TTTGATTC CACACCCTCGCAC-3′. Reaction conditions were denaturation at 94°C for 1 min; 40 cycles of 15 s at 94°C, 10 s at 50°C; extension at 72°C for 10 s. Reactions were carried out using a CFX96 System and analyzed using Bio-Rad CFX manager software v1.5 (Bio-Rad Laboratories).
In vitro cell viability assays
Cell viability assays were carried out using standard methods. 68 Briefly, cells were plated on 96-well plates at 1.5 × 10 3 cells per well. After 24 h, cells were treated with either dimethyl sulfoxide (1%) or 10-fold serial dilutions of JQ1 for 72 h. Cell viability was assessed by standard alamarBlue (Fisher Scientific) protocols. Fluorescence was measured at 590 nm using a microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA) to calculate IC 50 s (GraphPad Prism software, San Diego, CA, USA).
Bioinformatics
Raw values from NanoString were normalized using Partek Genomic Suite (PGS, St Louis, MI, USA) to house-keeping genes prior to paired group comparison (JQ1 versus VC). The log2-transformed fold difference between JQ1-and VC-treated mice was averaged across all five models for each gene and expression ranked from lowest to highest. Data were imported into GENE-E (version 3.0.214; Broad Institute, Cambridge, MA, USA) to generate a heatmap. The color intensity on the heat map reflects global expression with a minimum (25%) in blue and a maximum (75%) in red. Cluster analysis, using one-minus Pearson's correlation of rows only and distance for the clustering, was calculated using an average linkage algorithm. 69 
Statistics
Tumor volumes were compared by two-way analysis of variance and all values are presented as mean ± s.e.m. RNA expression (a minimum of three independent experiments for qRT-PCR) was compared by two-tailed t-test using GraphPad Prism 5.0 software. Po0.05 was considered significant.
